The Von Hippel-Lindau protein suppresses androgen receptor activity

Molecular Endocrinology

Volumn 28, Issue 2, 2014, Pages 239-248

  Wang, Jing ^a   Zhang, Wei ^a   Ji, Wei ^a   Liu, Xing ^a   Ouyang, Gang ^a   Xiao, Wuhan ^a  

^a INSTITUTE OF HYDROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; PROTEASOME; UBIQUITIN; VON HIPPEL LINDAU PROTEIN; ANDROGEN BINDING PROTEIN; DNA BINDING PROTEIN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROBASIN; PROSTATE SPECIFIC ANTIGEN; RNF6 PROTEIN, HUMAN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; VHL PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE PRODUCT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; CHEMISTRY; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DOMAIN; RAT; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANDROGEN-BINDING PROTEIN; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; GENE EXPRESSION; HEK293 CELLS; HUMANS; KALLIKREINS; PROMOTER REGIONS, GENETIC; PROSTATE-SPECIFIC ANTIGEN; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; RATS; RECEPTORS, ANDROGEN; SERINE ENDOPEPTIDASES; TRANSCRIPTIONAL ACTIVATION; UBIQUITINATION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84892527098     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1258     Document Type: Article

References (37)

1. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33-39.
2. Coffey K, Robson CN. Regulation of the androgen receptor by post-translational modifications. J Endocrinol. 2012;215(2):221-237.
3. Hammond-Martel I, Yu H, Affarel B. Roles of ubiquitin signaling in transcription regulation. Cell Signal. 2012;24(2):410-421.
4. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. Phosphorylationdependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 2002;21(15):4037-4048.
5. Chymkowitch P, Le May N, Charneau P, Compe E, Egly JM. The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J. 2011;30(3):468-479.
6. Xu K, Shimelis H, Linn DE, et al. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell. 2009;15(4):270-282.
7. Qi J, Tripathi M, Mishra R, et al. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell. 2013;23(3):332-346.
8. Sarkar S, Brautigan DL, Parsons SJ, Larner JM. Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene. 2014;33(1):26-33.
9. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein: an update. Methods Enzymol. 2007;435:371-383.
10. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998;1(7):959-968.
11. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol. 2003;13(1):83-89.
12. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem. 2000;275(33):25733-25741.
13. Iwai K, Yamanaka K, Kamura T, et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci USA. 1999;96(22): 12436-12441.
14. Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood. 2009;114(10):2015-2019.
15. Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol. 2003;5(1):64-70.
16. Xue J, Lv DD, Jiao S, et al. pVHL mediates K63-linked ubiquitination of nCLU. PloS One. 2012;7(4):e35848.
17. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol. 2010;7(5):277-288.
18. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008;8(12):967-975.
19. Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions. Cell Cycle. 2012;11(23):4462-4473.
20. Gamper AM, Qiao X, Kim J, et al. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Mol Cell. 2012;45(2):233-243.
21. Arias-González L, Moreno-Gimeno I, del Campo AR, et al. ERK5/ BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. Neoplasia. 2013;15(6):649-659.
22. Gordan JD, Lal P, Dondeti VR, et al. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008;14(6):435-446.
23. Anderson K, Nordquist KA, Gao X, et al. Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins. J Biol Chem. 2011;286(49):42027-42036.
24. Okuda H, Saitoh K, Hirai S, et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem. 2001;276(47):43611-43617.
25. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell. 2006;22(3):395-405.
26. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8(11):865-873.
27. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54(10):2577-2581.
28. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436-439.
29. Wissmann M, Yin N, Müller JM, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol. 2007;9(3):347-353.
30. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296(5567):550-553.
31. Feng X, Liu X, Zhang W, Xiao W. p53 directly suppresses BNIP3 expression to protect against hypoxia-induced cell death. EMBO J. 2011;30(16):3397-3415.
32. Su F, Pascal LE, Xiao W, Wang Z. Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53. Oncogene. 2010;29(3):421-431.
33. Kang HY, Yeh S, Fujimoto N, Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem. 1999;274(13): 8570-8576.
34. Wertz IE, O'Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature. 2004;430(7000):694-699.
35. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007; 2:145-173.
36. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG Jr. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997;28(4):459-464.
37. Cai C, He HH, Chen S, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011;20(4):457-471.